We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Growth stimulation of murine fibroblasts by TGF-β1 depends on the expression of a functional p53 protein.
- Authors
Dkhissi, Fatima; Raynal, Stéphane; Jullien, Pierre; Lawrence, David A
- Abstract
Transforming Growth Factor-β1 (TGF-β1) inhibits the proliferation of most cells, but stimulates some mesenchymal cell types, including murine NIH3T3 fibroblasts. We show here that TGF-β1 growth stimulation of NIH3T3 fibroblasts is reversed when these cells are transformed by SV40 or are transfected with a plasmid encoding the SV40 Large T antigen. Inversion of the TGF-β1 growth stimulation of NIH3T3 cells is not observed when these cells are transfected with plasmids expressing either a mutant Large T, unable to bind P53, or the E1A adenovirus oncoprotein which binds the retinoblastoma protein pRB but not P53. But when the TGF-β1-growth stimulated cells are transfected with a plasmid expressing a mutant form of Large T capable of binding to P53, but not to pRB, or with one expressing the E1B-55 kD adenovirus oncoprotein, which also binds to P53 but not to pRB, the cells are growth-inhibited by TGF-β1. The cdk inhibitor p21Waf is decreased in TGF-β1-stimulated NIH3T3 fibroblasts and increased in TGF-β1-inhibited SV40-transformed cells. Finally, we show that T12 fibroblasts, from a P53 knockout mouse, are growth inhibited by TGF-β1 and that they remain so upon transfection with a P53 which is mutant at restrictive temperature, but become growth-stimulated by this factor at permissive temperature when P53 is functional. These data strongly suggest that growth-stimulation of fibroblasts by TGF-β1 depends on the presence of a functional P53 protein and that inversion of this response occurs if P53 is absent or inactivated.
- Subjects
FIBROBLASTS; P53 protein; GROWTH factors; CELLS; ADENOVIRUSES; CELL proliferation
- Publication
Oncogene, 1999, Vol 18, Issue 3, p703
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/sj.onc.1202341